protein
| associating with RAD51, RAD52 proteins in the double strand RAD51/RAD52 repair pathway |
|
associating with UBL1 and TP53, involved in DNA recombination and essential for cell-cycle progression |
|
associating with FHIT for cell-cycle control |
|
interacting with ETV6 leading to sumoylation of ETV6 (TEL) by UBL (SUMO-1) |
|
interacted with the DNA-binding and ligand-binding domains of ESR1 |
|
protein interacting with UIMC1 |
|
interacted with SOX4 through HMG-box domain of SOX4 and represses its transcriptional activity independent of its SUMO-1-conjugating activity  |
|
interacting with STAR and FOXL2 (UBE2I-mediated sumoylation at lysine 25 of FOXL2 is required for transcriptional repression of the STAR gene and may be responsible for controlling the development of ovarian follicles) |
|
ZMYND11 interacts with PIAS1 (a well-characterized SUMO E3 enzyme) and UBE2I (the only SUMO E2 enzyme so far identified) through its distinct regions  |
|
molecular link between UBE2I and the metastasis genes such as CDC42 and CXCR4, and thus provide new insight into the mechanism by which UBE2I9 promotes tumor invasion and metastasis  |
|
binding of BRCA1 proteins to nuclear chaperone UE2I provides a novel mechanism for nuclear import and control of tumor growth  |
|
is an interaction partner of the transcription factor EGR2, a key regulator of hindbrain development  |
|
SETD8 interacts with the UBE2I E2 SUMO conjugating enzyme (directly binds SETD8 proximal to the catalytic SET domain) |
|
RANBP2 forms a stable complex with SUMO-modified RANGAP1 and UBE2I at the nuclear pore complex  |
|
SKI can enhance UBE2I-mediated cellular sumoylation, possibly through direct interaction with UBE2I  |
|
interaction between the CANX cytoplasmic domain and UBE2I, a SUMOylation E2 ligase, which modified the calnexin cytoplasmic domain by the addition of SUMO  |
|
UBE2I interacted directly with FYB1 and the association was increased in response to anti-CD3 stimulation  |